JenniferAngChanMD
Hematology • Boston, MAHematologic Oncology
Instructor in Medicine, Dana-Farber Cancer Institute
Dr. Chan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
# Dana
Boston, MA 02115Phone+1 617-632-6315Fax+1 617-632-5370
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006- Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
Harvard Medical SchoolClass of 2000
Certifications & Licensure
MA State Medical License 2003 - 2026
NH State Medical License 2023 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer Start of enrollment: 2005 Jul 01
- RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors Start of enrollment: 2008 May 01
- Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Start of enrollment: 2008 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Experience and Needs of Patients With Young-Onset Colorectal Cancer and Their Caregivers: A Qualitative Study.Kalen M Fletcher, Anna Revette, Andrea Enzinger, Leah Biller, Katelyn MacDougall
JCO Oncology Practice. 2024-12-01 - 1 citationsClinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ g...Harshabad Singh, Kristen E Lowder, Kevin Kapner, Ronan J Kelly, Hui Zheng
Nature Communications. 2024-08-09 - 2 citationsDesign and Implementation of an Opt-Out, End-to-End, PreemptiveTesting Program for Patients Planned for a Systemic Fluoropyrimidine.Joseph O Jacobson, Garrett Rompelman, Angela Chen, Samantha Morrison-Ma, Lindsay Murray
JCO Oncology Practice. 2024-08-01
Other
- Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growthChan JA, Kulke M
http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-optio
UpToDate, Wolters Kluwer Health - 2013-04-15 - Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoringChan JA, Kulke M
http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-presentatio
UpToDate, Wolters Kluwer Health - 2012-07-05 - Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretionChan JA, Kulke M
http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-systemic-th
UpToDate, Wolters Kluwer Health - 2013-02-05
Press Mentions
Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine TumoursOctober 25th, 2024- Cabozantinib Improves PFS for Advanced Neuroendocrine TumorsSeptember 17th, 2024
- Team Publishes Results from Clinical Trial Evaluating Cabozantinib in Advanced Neuroendocrine TumorsSeptember 16th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
